# The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

> **NCT04798716** · PHASE1,PHASE2 · UNKNOWN · sponsor: **AVEM HealthCare** · enrollment: 55 (estimated)

## Conditions studied

- Covid19
- Novel Coronavirus Pneumonia
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)
- **DRUG:** MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)
- **DRUG:** MSC-exosomes delivered intravenously every other day (8:8:8)

## Key facts

- **NCT ID:** NCT04798716
- **Lead sponsor:** AVEM HealthCare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09
- **Primary completion:** 2024-09
- **Final completion:** 2024-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04798716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04798716, "The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04798716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*